This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Treatment-Emergent Psychosis With Aripiprazole

Matthew E. Barnas, MD; Najeeb Hussain, MD; and Georgios Petrides, MD

Published: October 14, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole, the latest atypical antipsychotic to receiveapproval by the U.S. Food and Drug Administration, is uniquein its action as a partial agonist at dopamine receptors.1 Partialagonists can function as net agonists or net antagonists, dependingon the amount of naturally occurring full agonist neurotransmitterthat is present. Aripiprazole has antagonist activityat dopamine-2 (D2) receptors in a hyperdopaminergic environmentand agonist activity in a hypodopaminergic environment.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...